Welcome!

News Feed Item

Castlight Health Announces Second Quarter 2014 Results

Castlight Health®, Inc. (NYSE:CSLT), a pioneer of the Enterprise Healthcare Cloud, today announced results for its second quarter ended June 30, 2014.

“Demand for Castlight’s Enterprise Healthcare Cloud remains strong as large organizations are increasingly evaluating enterprise healthcare technology to gain control of their healthcare spending,” said Giovanni Colella, M.D., co-founder and Chief Executive Officer of Castlight Health. “We ended the second quarter with 130 customers and expanded our Fortune 500 customer list by more than 20 percent. New large customers included Google, Kellogg Company, Texas Instruments and Sprint Corporation, among others. Further, we continue to execute well. We launched 13 additional customers during the second quarter, including CalPERS, and implemented Castlight Pharmacy and Castlight Rewards for 12 existing customers.”

Colella continued, “We continue to launch new products and lead the way with technologies that enable innovative benefit designs for our customers. We were pleased to announce the upcoming launch of Castlight Dental, which is the newest significant expansion of our Castlight Care Solution Center alongside Castlight Medical and Castlight Pharmacy.”

Financial Performance for the Three Months Ended June 30, 2014

  • Total revenue for the second quarter of 2014 was $10.5 million, an increase of 353% from the second quarter of 2013. Subscription revenue was $9.6 million, an increase of 359% on a year-over-year basis. Professional services revenue was $1.0 million, an increase of 304% compared with the same period last year.
  • Gross margin for the second quarter of 2014 was 29.6%, compared to a gross loss of 64.9% in the second quarter of 2013. Non-GAAP gross margin for the second quarter of 2014 was 32.6% compared to a gross loss of 63.9% in the second quarter of 2013.
  • Operating loss for the second quarter of 2014 was $21.8 million, compared to an operating loss of $14.2 million during the second quarter of 2013. Non-GAAP operating loss for the second quarter of 2014 was $18.8 million, compared to a non-GAAP operating loss of $13.7 million during the second quarter of 2013.
  • Net loss per basic and diluted share was ($0.24) in the second quarter of 2014, compared to a loss of ($1.47) per share in the second quarter of 2013. The non-GAAP net loss per share for the second quarter of 2014 was ($0.21), compared to a loss of ($1.43) per share in the second quarter of 2013. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the second quarter of 2014 was 89.5 million compared to 9.6 million in the second quarter of 2013.
  • Total cash, cash equivalents and marketable securities were $217.9 million at the end of the second quarter of 2014, compared to $239.7 million at the end of last quarter. Cash used in operations for the second quarter of 2014 was $19.6 million, compared to $16.1 million used in operations last quarter.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

Business Outlook

Q3 2014 Guidance: Revenue for the company’s third fiscal quarter is expected to be in the range of $11.3 million to $11.6 million, an increase of 214% to 222% year-over-year. Non-GAAP operating loss is expected to be in the range of ($18.7) million to ($19.0) million. Non-GAAP basic and diluted loss per share is expected to be approximately ($0.21) based on 90.0 million weighted average basic and diluted common shares outstanding.

Full Year 2014 Guidance: Revenue for the company’s full year 2014 is expected to be in the range of $42.6 million to $43.2 million, an increase of 228% to 232% year-over- year. Non-GAAP operating loss is expected to be in the range of ($75.0) million to ($76.0) million. Non-GAAP basic and diluted loss per share is expected to be in the range of ($1.00) to ($1.01) based on 75.0 million weighted average basic and diluted common shares outstanding.

For both the third quarter and the full year 2014, non-GAAP estimates exclude the effects of stock-based compensation expense and warrant expense.

Leadership Updates

Castlight Health announced today that Randy Womack, chief operating officer, will step down September 30, 2014 after nearly four years of service with the company. Mr. Womack’s responsibilities will be assumed by other members of Castlight’s management team after a seamless transition process is completed.

Additionally, Concur CEO Steve Singh has joined Castlight’s Board of Directors, effective immediately. Concurrently, directors Bob Kocher, M.D., partner at Venrock, and Christopher P. Michel, managing director at Nautilus Ventures, departed the Board. Dr. Kocher will remain as an advisor to the company, and Bryan Roberts, co-founder of Castlight and general partner at Venrock, remains Castlight’s Chairman of the Board. These changes follow the April addition of Ed Park, executive vice president and chief operating officer of athenahealth to the Board of Directors.

“We would like to thank Randy for his efforts to help make Castlight such a great company and achieve such strong momentum as a business. Randy has decided to leave the company with the success of his third IPO to pursue his passion for startups. We wish him every success in his future endeavors,” said Colella. “Moving forward, Castlight has an incredibly strong group of experienced, proven leaders. I look forward to working with them to continue to capture growth and realize innovation opportunities.”

Quarterly Conference Call

Castlight Health will host a conference call to discuss its second quarter results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company's Investor Relations website at http://ir.castlighthealth.com. In addition, an archive of the audiocast can be accessed through the same link. Participants who choose to call in to the conference call can do so by dialing 1-201-689-8562. A replay will be available at 1-858-384-5517, passcode 13586458, until midnight (Eastern Time) August 5, 2014.

About Castlight Health

Castlight Health, Inc. (NYSE: CSLT) believes great healthcare builds great business. The Castlight Enterprise Healthcare Cloud enables employers to deliver cost-effective benefits, provides medical professionals and health plans a merit-based market to showcase their services, and – most importantly – empowers employees to make informed choices with a clear understanding of costs and likely outcomes. For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook. Source: Castlight Health.

Non-GAAP Financial Measures

To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin (loss), non-GAAP operating expense, non-GAAP operating loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, expense for a warrant issued to a third-party service provider and the associated tax impact of these items, where applicable.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the third quarter and full fiscal year of 2014 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and warrant expense, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and warrant expense are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor For Forward-Looking Statements

This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s third quarter and full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2014 Castlight Health, Inc. Castlight Health, Castlight, Castlight Medical, Castlight Pharmacy, Castlight Dental, Castlight Care Solution Center are trademarks and/or registered trademarks of Castlight Health Inc. in the United States and other countries. Other company and product names may be trademarks of the respective companies with which they are associated.

 
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
     
 
As of
June 30, December 31,
2014 2013
(unaudited)
Assets
Current assets:
Cash and cash equivalents $ 35,268 $ 25,154
Marketable securities 124,560 42,017
Accounts receivable, net 10,392 5,065
Deferred commissions 2,946 3,648
Prepaid expenses and other current assets   3,010   1,583  
Total current assets 176,176 77,467
 
Property and equipment, net 3,164 2,631
Marketable securities, noncurrent 58,095 -

Restricted cash, noncurrent

- 101
Deferred commissions, noncurrent 1,648 1,821
Other assets   380   1,497  
Total assets $ 239,463 $ 83,517  
 
Liabilities, convertible preferred stock and stockholders' equity (deficit)
 
Current liabilities:
Accounts payable $ 2,928 $ 2,536
Accrued expenses and other current liabilities 3,937 4,998
Accrued compensation 6,984 8,064
Deferred revenue   13,970   6,925  
Total current liabilities 27,819 22,523
 
Deferred revenue, noncurrent 5,780 4,548
Other liabilities, noncurrent   317   373  
Total liabilities 33,916 27,444
Commitments and contingencies
Convertible preferred stock - 180,423
Stockholders' equity (deficit)   205,547   (124,350 )
Total liabilities, convertible preferred stock and stockholders' equity (deficit) $ 239,463 $ 83,517  
 
         
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
 
 
Three Months Ended June 30, Six Months Ended June 30,
  2014     2013     2014     2013  
Revenue:
Subscription $ 9,576 $ 2,088 $ 17,039 $ 3,827
Professional services   957     237     1,870     405  
Total revenue   10,533     2,325     18,909     4,232  
Cost of revenue:
Cost of subscription (1) 2,915 1,460 5,627 2,664
Cost of professional services (1)   4,502     2,373     8,373     4,426  
Total cost of revenue   7,417     3,833     14,000     7,090  
Gross profit (loss)   3,116     (1,508 )   4,909     (2,858 )
Operating expenses:
Sales and marketing (1) 14,947 7,108 31,507 12,873
Research and development (1) 5,476 3,616 11,003 6,524
General and administrative (1)   4,519     1,981     8,529     3,441  
Total operating expenses   24,942     12,705     51,039     22,838  
Operating loss (21,826 ) (14,213 ) (46,130 ) (25,696 )
Other income, net   50     40     73     90  
Net loss $ (21,776 ) $ (14,173 ) $ (46,057 ) $ (25,606 )
 
Net loss per share, basic and diluted $ (0.24 ) $ (1.47 ) $ (0.86 ) $ (2.71 )
 
Weighted-average shares used in basic and diluted net loss per share   89,520     9,619     53,284     9,438  
 
 
(1)Includes stock-based compensation expense as follows:
 
Three Months Ended June 30, Six Months Ended June 30,
  2014     2013     2014     2013  
 
Cost of revenue:
Cost of subscription $ 35 $ - $ 39 $ 1
Cost of professional services 280 23 420 52
Sales and marketing 1,152 225 2,326 408
Research and development 493 61 914 110
General and administrative 980 156 1,794 272
 
         
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 
 
Three Months Ended June 30, Six Months Ended June 30,
2014 2013 2014 2013
Operating activities:
Net loss $ (21,776 ) $ (14,173 ) $ (46,057 ) $ (25,606 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation 322 113 604 213
Stock-based compensation 2,940 465 5,493 843
Amortization of deferred commission 868 196 2,244 325
Accretion and amortization of marketable securities 373 193 497 421
Expense related to issuance of warrant 70 - 2,499 -
Changes in operating assets and liabilities:
Accounts receivable (4,077 ) (1,412 ) (5,327 ) (1,387 )
Deferred commissions (1,087 ) (700 ) (1,369 ) (1,267 )
Prepaid expenses and other assets (596 ) (435 ) (1,677 ) (535 )
Accounts payable (375 ) 849 384 279
Accrued expenses and other liabilities 2,173 2,406 (1,203 ) 1,109
Deferred revenue   1,591     2,493     8,277     3,446  
Net cash used in operating activities   (19,574 )   (10,005 )   (35,635 )   (22,159 )
 
Investing activities
Decrease restricted cash, net 101 - 101 -
Purchase of property and equipment (311 ) (408 ) (967 ) (1,118 )
Purchase of marketable securities (126,442 ) (8,382 ) (162,175 ) (16,480 )
Sales of marketable securities - - 13,000 5,000
Maturities of marketable securities   3,000     39,075     8,000     44,075  
Net cash (used in) provided by investing activities   (123,652 )   30,285     (142,041 )   31,477  
 
Financing activities
Proceeds from the exercise of stock options 106 154 1,628 200
Payments of deferred financing costs (1,679 ) - (3,781 ) -

Net proceeds from initial public offering

  -     -     189,943     -  
Net cash (used in) provided by financing activities   (1,573 )   154     187,790     200  
 
Net increase (decrease) in cash and cash equivalents (144,799 ) 20,434 10,114 9,518
Cash and cash equivalents at beginning of the period   180,067     31,618     25,154     42,534  
Cash and cash equivalents at end of the period $ 35,268   $ 52,052   $ 35,268   $ 52,052  
 
   
CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)
 
Three Months Ended Six Months Ended
June 30, March 31, June 30, June 30, June 30,
2014 2014 2013 2014 2013
Gross profit (loss):

GAAP gross profit subscription

$ 6,661 $ 4,751 $ 628 $ 11,412 $ 1,163
GAAP gross margin subscription 69.6 % 63.7 % 30.1 % 67.0 % 30.4 %
Stock-based compensation expense included in cost of revenue subscription   35     4     -     39     1  
Non-GAAP gross profit subscription $ 6,696   $ 4,755   $ 628   $ 11,451   $ 1,164  
Non-GAAP gross margin subscription 69.9 % 63.7 % 30.1 % 67.2 % 30.4 %
 
GAAP gross loss professional services $ (3,545 ) $ (2,958 ) $ (2,136 ) $ (6,503 ) $ (4,021 )
GAAP gross loss percentage professional services (370 ) % (324 ) % (901 ) % (348 ) % (993 ) %
Stock-based compensation expense included in cost of revenue professional services   280     140     23     420     52  
Non-GAAP gross loss professional services $ (3,265 ) $ (2,818 ) $ (2,113 ) $ (6,083 ) $ (3,969 )
Non-GAAP gross loss percentage professional services (341 ) % (309 ) % (892 ) % (325 ) % (980 ) %
 
GAAP gross profit (loss) $ 3,116 $ 1,793 $ (1,508 ) $ 4,909 $ (2,858 )
GAAP gross margin (loss percentage) 29.6 % 21.4 % (64.9 ) % 26.0 % (67.5 ) %
Impact of non-GAAP adjustments   315     144     23     459     53  
Non-GAAP gross profit (loss) $ 3,431   $ 1,937   $ (1,485 ) $ 5,368   $ (2,805 )
Non-GAAP gross margin (loss percentage) 32.6 % 23.1 % (63.9 ) % 28.4 % (66.3 ) %
 
Operating expense:
GAAP sales and marketing $ 14,947 $ 16,560 $ 7,108 $ 31,507 $ 12,873
Expense related to warrant (70 ) (2,429 ) - (2,499 ) -
Stock-based compensation expense included in sales and marketing   (1,152 )   (1,174 )   (225 )   (2,326 )   (408 )
Non-GAAP sales and marketing $ 13,725   $ 12,957   $ 6,883   $ 26,682   $ 12,465  
 
GAAP research and development $ 5,476 $ 5,527 $ 3,616 $ 11,003 $ 6,524
Stock-based compensation expense included in research and development   (493 )   (421 )   (61 )   (914 )   (110 )
Non-GAAP research and development $ 4,983   $ 5,106   $ 3,555   $ 10,089   $ 6,414  
 
GAAP general and administrative $ 4,519 $ 4,010 $ 1,981 $ 8,529 $ 3,441
Stock-based compensation expense included in general and administrative   (980 )   (814 )   (156 )   (1,794 )   (272 )
Non-GAAP general and administrative $ 3,539   $ 3,196   $ 1,825   $ 6,735   $ 3,169  
 
GAAP operating expenses $ 24,942 $ 26,097 $ 12,705 $ 51,039 $ 22,838
Impact of non-GAAP adjustments   (2,695 )   (4,838 )   (442 )   (7,533 )   (790 )
Non-GAAP operating expenses $ 22,247   $ 21,259   $ 12,263   $ 43,506   $ 22,048  
 
Operating loss:
GAAP operating loss $ (21,826 ) $ (24,304 ) $ (14,213 ) $ (46,130 ) $ (25,696 )
Impact of non-GAAP adjustments   3,010     4,982     465     7,992     843  
Non-GAAP operating loss $ (18,816 ) $ (19,322 ) $ (13,748 ) $ (38,138 ) $ (24,853 )
 
Net loss and net loss per share:
GAAP net loss $ (21,776 ) $ (24,281 ) $ (14,173 ) $ (46,057 ) $ (25,606 )
Total pre-tax impact of non-GAAP adjustments 3,010 4,982 465 7,992 843
Income tax impact of non-GAAP adjustments   -     -     -     -     -  
Non-GAAP net loss $ (18,766 ) $ (19,299 ) $ (13,708 ) $ (38,065 ) $ (24,763 )
 
Basic and Diluted net loss per share
GAAP $ (0.24 ) $ (0.90 ) $ (1.47 ) $ (0.86 ) $ (2.71 )
Non-GAAP $ (0.21 ) $ (0.72 ) $ (1.43 ) $ (0.71 ) $ (2.62 )
 
Shares used in basic and diluted net loss per share computation   89,520     26,970     9,619     53,284     9,438  
 
Free Cash Flow
 
GAAP net cash flow used in operating activities $ (19,574 ) $ (16,061 ) $ (10,005 ) $ (35,635 ) $ (22,159 )
Purchase of property and equipment   (311 )   (656 )   (408 )   (967 )   (1,118 )
Free cash flow $ (19,885 ) $ (16,717 ) $ (10,413 ) $ (36,602 ) $ (23,277 )
 

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band-aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It does...
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...